Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome

Glatz, Torben; Bronsert, Peter; Schäfer, Markus; Kulemann, Birte; Marjanović, Goran; Sick, Olivia; Hopt, Ulrich T.; Zirlik, Katja; Makowiec, Frank; Hoeppner, Jens

doi:10.1016/j.ejso.2015.07.010

Cited by 39 publications

(38 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other European colleagues recently reported comparable findings of significantly improved 5 year survival when there is a histopathological response to chemotherapy, from a small study (134 patients) with comparatively short follow‐up (median 2.8 years), including only T3‐T4 tumors. They also examined the particular value of the adjuvant portion of chemotherapy, and when administered to those with chemotherapy response, similarly showed an improved 5 year survival.…”

Section: Discussionmentioning

confidence: 60%

The role of adjuvant platinum‐based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery

Saunders

Bowman

Reece-Smith

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 60%

The role of adjuvant platinum‐based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery

Saunders

Bowman

Reece-Smith

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…The addition of CTC detection to intra-therapeutic re-staging procedures and the comparison of the results to pre-therapeutic CTC detection values could also possibly identify patients with either strong or limited response to neoadjuvant treatment. If the presence of CTC following neoadjuvant chemotherapy or chemoradiation could contribute to the currently available prognostic information, it will help to identify non-metastatic EAC patients at high risk for disease progression who may derive benefit from additional adjuvant therapies or inclusion into clinical trials of novel therapies for high-risk patients [47].…”

Section: Future Clinical Implications Of Ctc In Eacmentioning

confidence: 99%

Circulating Tumor Cells in Esophageal Cancer

Hoeppner¹,

Kulemann

2017

Oncol Res Treat

View full text Add to dashboard Cite

Esophageal cancer (EC) is mostly diagnosed due to clinical symptoms such as dysphagia or anemia. Depending on the staging and the histological subtype, squamous cell carcinoma or adenocarcinoma, patients with non-metastasized disease mostly undergo neoadjuvant chemoradiation or perioperative chemotherapy followed by esophageal resection. Nearly 50% of the curatively treated patients develop distant metastasis within 5 years, although no metastases were clinically evident at time of treatment. More recently, the concept of circulating tumor cells (CTC) has also been introduced for EC. CTC are thought to be the means of systemic tumor spread, with the ability to set up metastases in distant organs. Much effort has been made to capture, enrich and detect these very rare cells from the blood stream of EC patients. CTC have been found to be independent risk factors for worse prognosis in patients with EC. Pre- and intra-therapeutic CTC enrichment and detection has the potential to improve preoperative staging, and provide a differential indication for neoadjuvant therapeutic modality and an indication for adjuvant therapy.

show abstract

“…The result of Korean NCIT 01515748 study of docetaxel, oxaliplatin and tegafur as neo-adjuvant chemotherapy is still pending. A German study by Glatz et al 35 demonstrated the survival advantage of using…”

Section: Discussionmentioning

confidence: 99%

Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer

Chang¹,

Foo

Koo

et al. 2016

BMJ Open Gastroenterol

View full text Add to dashboard Cite

BackgroundNeoadjuvant chemotherapy improves survival of locally advanced gastric cancer patients. However, benefit is limited and the best regimen remains controversial.ObjectivesOur primary objective of this prospective, multicenter phase 2 study was to evaluate the pathological complete response rate (PCR) with 2 cycles of docetaxel and capecitabine.MethodsTo be eligible, patients had to have histologically documented gastric cancer, a ECOG performance status 0 or 1, T3or4 Nany M0 staging after oesophagogastroduodenoscopy (OGD), endoscopic ultrasound (EUS), CT scan of thorax and abdomen, and negative laparoscopic examination and peritoneal washing. Eligible patients received two cycles of intravenous docetaxel 60 mg/m2 on day 1 and oral capecitabine 900 mg/m2 two times per day from day 1 to day 14 every 3 weeks. We evaluated the response by CT scan and EUS. The patients underwent curative resection with D2 lymphadenectomy subsequently.Results18 patients were enrolled in the study: 66% were male and the median age was 60 years. 17 patients had T3 disease at diagnosis. There was no pCR noted. 4 patients had a partial response of 22% (95% CI: 7–42%), 8 patients had stable disease and 3 patients had disease progression. The median survival was 17.1 months with 3 long-term survivors after at least 3 years of follow-up. The treatment was well tolerated with neutropenia being the most common toxicity. We observed 22% grade III and 33% grade IV neutropenia, but no neutropenic fever or death was observed from chemotherapy.ConclusionNeo-adjuvant chemotherapy with docetaxel and capecitabine has limited activity against GC. More effective treatment regimens are needed urgently.Trial registration numberNCT00414271.

show abstract

Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome

Cited by 39 publications

References 21 publications

The role of adjuvant platinum‐based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery

The role of adjuvant platinum‐based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery

Circulating Tumor Cells in Esophageal Cancer

Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer

Contact Info

Product

Resources

About